Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9876 · 1 trial · 1 indication
Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP)) is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), participant's global assessment of disease activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and C-Reactive Protein (CRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| Arm | Type | Description |
|---|---|---|
| GS-9876 - 30 mg | EXPERIMENTAL | GS-9876 30 mg + filgotinib placebo for 12 weeks |
| GS-9876 - 10 mg | EXPERIMENTAL | GS-9876 10 mg + filgotinib placebo for 12 weeks |
| Filgotinib | EXPERIMENTAL | Filgotinib + GS-9876 placebo for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | GS-9876 placebo + filgotinib placebo for 12 weeks |
| Name | Type | Description |
|---|---|---|
| GS-9876 | DRUG | One tablet administered orally once daily |
| Filgotinib | DRUG | Two tablets administered orally once daily |
| GS-9876 placebo | DRUG | One tablet administered orally once daily |
| Filgotinib placebo | DRUG | Two tablets administered orally once daily |
| Methotrexate | DRUG | Background therapy with methotrexate administered orally or parenterally once weekly |
Key Inclusion Criteria: * Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1 * Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25 mg/week continuously for at least 1...
Top 20 of 28 competitors
GS-9876 is an investigational small molecule being studied for the treatment of active rheumatoid arthritis. It is designed to be used in combination with background methotrexate therapy. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
GS-9876 is a small molecule developed by Gilead Sciences for rheumatoid arthritis. While its specific molecular target is not publicly disclosed in the available clinical trial information, it is being evaluated for its safety, tolerability, and efficacy in patients with active disease who are on background methotrexate therapy.
GS-9876 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the drug's potential as a treatment for rheumatoid arthritis.
GS-9876 is in Phase 2 clinical development. A Phase 2 clinical trial has been completed to assess its safety, tolerability, and efficacy in participants with active rheumatoid arthritis. The drug remains investigational and is not yet approved for any use.
GS-9876 has been studied in one completed Phase 2 clinical trial, identified as NCT02885181. This randomized, double-blind, placebo-controlled trial enrolled 83 participants with active rheumatoid arthritis on background methotrexate therapy, across multiple countries including the United States, Bulgaria, Czechia, Georgia, Moldova, Poland, and Ukraine.
GS-9876 is the investigational code name used by Gilead Sciences for this small molecule. No alternative brand names or other designations have been disclosed in the clinical trial information. It is distinct from other drugs and is being evaluated specifically for rheumatoid arthritis.